Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer OTC Drugs

Enamelon stock surges 288%, leads NASDAQ gainers through first three months.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

ENAMELON STOCK JUMPS 288% IN FIRST QUARTER to lead all gainers on the NASDAQ exchange. The Yonkers, N.Y.-based start-up oral care company closed March 31 at 24-1/4 -- an 18-point jump from the 6-1/4 closing price on Dec. 31. The issue outperformed all other stocks on the exchange, finishing 188 percentage points above the second place gainer. Enamelon closed at 21-5/8 on April 4.

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Table

View full table

Topics

Tags:
Consumer OTC Drugs
UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By